POS0841 RISK FACTORS OF LOW BONE MINERAL DENSITY IN WOMEN WITH SYSTEMIC SCLEROSIS

نویسندگان

چکیده

Background: Chronic inflammatory rheumatic diseases are risk factors of bone loss and fractures. Systemic sclerosis (SSc) has been recognized to be another potential joint disease that may affect tissue. Objectives: evaluate mineral density (BMD) low BMD in women with SSc. Methods: 173 women, among them 110 postmenopausal (median age 60[55,63] years) 63 premenopausal 35[31,44] years). was measured at lumbar spine (LS), femoral neck (FN) total hip (TH) by dual energy X-ray absorptiometry (DXA, Hologic 4500A). Low diagnosed if the T-score < -1.0 standard deviation (SD) Z-score -2.0 SD women. The relationship between SSc patients’ characteristics evaluated using univariate linear regression analysis. Results: found 66% patients: 79% - 18% Among persons osteoporosis discovered 47% osteopenia – 32% cases. In woman LS, FN TH were associated body mass index (BMI) (β=0.27, p=0.010; β=0.47, p<0,001 β=0.45, p<0,001, respectively), duration glucocorticoids (GCs) (β=-0.31, p=0.008; β=-0.34, p=0.003 β=-0.27, p=0.022, respectively); C-reactive protein (β= -0.32, p=0.016 β= -0.29, p=0.029, respectively) LS current cumulative GCs dose -0.24, p=0.039 p=0.014, respectively). BMI (β=0.51, p<0,001; p=0.002, -0.45, p=0.004; -0.47, -0.48, p=0.002; -0.51, p=0.001 -0.46, p=0.004, 25(ОН)D level (β=0.52, p=0.008 β=0.54, p=0.005, -0.44, p=0.004). Conclusion: BMI, independent for both persons. Additional as vitamin D out Disclosure Interests: None declared

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Prognostic factors of low bone mineral density in systemic sclerosis.

OBJECTIVE To analyse the results of bone densitometry in patients with systemic sclerosis (SSc), evaluating the prognostic factors of low bone mineral density (BMD) in fertile and postmenopausal patients, and comparing to a control healthy group. METHODS Cross-sectional study analysing 61 female SSc patients, aged 25 to 51 years, who performed a bone densitometry using dual x-ray absorptiomet...

متن کامل

[Factors associated with low bone mineral density among white women].

OBJECTIVE To analyze whether the factors causing low bone mineral density among elderly women are the same as those observed in other age groups. METHODS A cross-sectional study was carried out on the medical records of a random sample of 413 white women seen at an imaging diagnostics service in a city of Southern Brazil, in 2003. Femoral bone mineral densities with adjustment using T-scores ...

متن کامل

Low Bone Mineral Density and Associated Factors in Patients with Cystic Fibrosis: A Cross-Sectional Study

Background: Failure to maintain bone mass density is a major complication in patients with cystic fibrosis (CF). This study was conducted to evaluate the prevalence of low bone mineral density (BMD) and also identifying associated risk factors in CF patients. Materials and Methods: Present study conducted on 59 CF patients aged 5-35 years referred to respiratory clinic of Masih Daneshvari Hospi...

متن کامل

Prevalence of Low Bone Mineral Density and Associated Risk Factors in Korean Puerperal Women

Although pregnancy is a medical condition that contributes to bone loss, little information is available regarding bone mineral density (BMD) in puerperal women. This cross sectional study aimed to evaluate the prevalence of low BMD in puerperal women and to identify associated risk factors. We surveyed all puerperal women who had BMD measurements taken 4-6 weeks after delivery in a tertiary un...

متن کامل

Romosozumab in postmenopausal women with low bone mineral density.

BACKGROUND Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. METHODS In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Annals of the Rheumatic Diseases

سال: 2021

ISSN: ['1468-2060', '0003-4967']

DOI: https://doi.org/10.1136/annrheumdis-2021-eular.1339